PLEASE NOTE: This event is informational only and not part of the routine OB/GYN Department Grand Rounds. As such, no CME will be provided by attending.
"Uterine Fibroids: Overview and Update on ACOG guidelines, including pivotal trial data of Myfembree (relugolix/ethinyl estradiol/NETA)," will provide a brief overview of selected patient-reported outcome measures.
- Provide a brief overview of uterine fibroid epidemiology and demographics (Dr. Juhn).
- Provide a simplified, tabular format of ACOG 2021 guidelines for management of uterine fibroids (Dr. Juhn).
- Review the two pivotal clinical trial data of Myfembree (relugolix/ethinyl estradiol/NETA) which led to FDA approval (Dr. Juhn).
- Provide a high-level overview of selected patient reported outcomes measures (PROMs) in uterine fibroids (Dr. Tellor).
Mark Juhn, D.O.
Sr. Director, Field Medical Director
Women’s Health and Metabolism
Katie Tellor, PharmD, FACC, BCPS
Director, Internal Medicine Field Medical Outcomes & Analytics